Quick Answer
PUMA BIOTECHNOLOGY, INC. reported Long-Term Debt of $0.00 for fiscal year 2025.
PUMA BIOTECHNOLOGY, INC. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $21.72M | -66.9% |
| 2023 | $65.66M | -33.2% |
| 2022 | $98.31M | +1.3% |
| 2021 | $97.09M | +15.6% |
| 2020 | $84.03M | -11.5% |
| 2019 | $94.96M | -37.5% |
| 2018 | $151.89M | +213.3% |
| 2017 | $48.48M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $10.87M | -75.1% | +2.1% |
| March 31, 2025 | $10.65M | -80.5% | -51.0% |
| December 31, 2024 | $21.72M | -66.9% | -33.7% |
| September 30, 2024 | $32.75M | -57.3% | -25.1% |
| June 30, 2024 | $43.73M | -50.1% | -20.0% |
| March 31, 2024 | $54.69M | -44.5% | -16.7% |
| December 31, 2023 | $65.66M | -33.2% | -14.3% |
- PUMA BIOTECHNOLOGY, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2017–2025 period, PUMA BIOTECHNOLOGY, INC.’s long-term debt has declined by 100.0% (from $48.48 million to $0.00).
- The most recent figure is from PUMA BIOTECHNOLOGY, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: